Glenmark Hits Record High, Surges 10% on Breakthrough Licensing Deal

soared 20% on July 11, 2025, hitting the upper circuit and marking a fresh all-time high of ₹2,284.80, surpassing its previous peak. The recent rally was fueled by a major development: Glenmark’s arm, IGI Therapeutics SA, announced an exclusive global licensing agreement with AbbVie, a leading global biopharmaceutical company. The deal focuses on the development and commercialization of ISB 2001, a promising candidate targeting cancer and autoimmune diseases. This strategic partnership not only validates Glenmark’s R&D capabilities but also unlocks global revenue potential through milestone and royalty payments. The market responded with strong buying interest, reflecting optimism around future earnings and long-term growth. Disclaimer: This post is intended solely for informational purposes and should not be construed as a recommendation to buy, sell, or hold any security. Investors/Traders are advised to consult their certified financial advisor before making any investment decisions.